IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between its headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: People, Innovation, Quality and Responsibility.
IBSA Farmaceutici, founded in 1992, is part of IBSA (Institut Biochimique SA) and has its headquarters in Lodi, where the first plant was born. Over the years, IBSA has grown rapidly, expanding its production plant in Cassina de’ Pecchi (Milan) and three R&D labs, becoming a leading economic and scientific player in the Italian pharmaceutical sector. Currently, IBSA employs over 500 people in Italy. Technology, scientific know-how and R&D investments have allowed the Company to build an extensive product portfolio covering 10 therapeutic areas over the time. Drugs, medical devices and food supplements are developed and produced in Italy from our people and sold in more than 90 countries worldwide. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.
IBSA FARMACEUTICI ITALIA SRL
Via Martiri di Cefalonia, 2
26900, Lodi – Italia
Tel: +39 0371 617 1 INT. 347
Fax: +39 0371 617 368
We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company’s approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology,…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
